menu search

Regencell bioscience's covid-19 candidate shows encouraging action on mild to moderate symptoms

Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the results from the EARTH efficacy trial of its COVID-19 ...

February 17, 2022, 11:40 am

Open orphan client sees positive results in human challenge study

Open Orphan PLC (AIM:ORPH, OTC:OPORF) has highlighted positive results of a human challenge study assessing Enanta Pharmaceuticals (NASDAQ:ENTA)' resp...

February 17, 2022, 8:31 am

Open orphan client sees positive results in human challenge study

Open Orphan PLC (AIM:ORPH, OTC:OPORF) has highlighted positive results of a human challenge study assessing Enanta Pharmaceuticals (NASDAQ:ENTA)' resp...

February 17, 2022, 8:31 am

Open orphan client sees positive results in human challenge study

Open Orphan PLC (AIM:ORPH, OTC:OPORF) has highlighted positive results of a human challenge study assessing Enanta Pharmaceuticals (NASDAQ:ENTA)' resp...

February 17, 2022, 8:31 am

Icer's report suggests benefits of eli lilly's tirzepatide not better than other diabetes drugs

Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co's (NYSE: LLY) tirzepatide, a type II diabetes ...

February 16, 2022, 1:57 pm

Icer's report suggests benefits of eli lilly's tirzepatide not better than other diabetes drugs

Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co's (NYSE: LLY) tirzepatide, a type II diabetes ...

February 16, 2022, 1:57 pm

Icer's report suggests benefits of eli lilly's tirzepatide not better than other diabetes drugs

Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co's (NYSE: LLY) tirzepatide, a type II diabetes ...

February 16, 2022, 1:57 pm

Keep an eye on digital turbine's acquisitions to work and bring results

The APPS stock is a prime candidate for investors liking growth, however, the valuation is rich in a ye...

February 16, 2022, 1:10 pm

Keep an eye on digital turbine's acquisitions to work and bring results

The APPS stock is a prime candidate for investors liking growth, however, the valuation is rich in a ye...

February 16, 2022, 1:10 pm

Keep an eye on digital turbine's acquisitions to work and bring results

The APPS stock is a prime candidate for investors liking growth, however, the valuation is rich in a ye...

February 16, 2022, 1:10 pm

Biovaxys says studies on bvx-0320, its haptenized sars-cov-2 s-spike protein vaccine, suggest superior cardiac safety

BioVaxys Technology Corp has revealed that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine ...

February 16, 2022, 9:48 am

Biovaxys says studies on bvx-0320, its haptenized sars-cov-2 s-spike protein vaccine, suggest superior cardiac safety

BioVaxys Technology Corp has revealed that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine ...

February 16, 2022, 9:48 am

Biovaxys says studies on bvx-0320, its haptenized sars-cov-2 s-spike protein vaccine, suggest superior cardiac safety

BioVaxys Technology Corp has revealed that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine ...

February 16, 2022, 9:48 am

Phirbo's (pahc) dyadic deal to fortify animal vaccine wing

Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine ...

February 15, 2022, 12:20 pm

Phirbo's (pahc) dyadic deal to fortify animal vaccine wing

Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine ...

February 15, 2022, 12:20 pm

Phirbo's (pahc) dyadic deal to fortify animal vaccine wing

Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine ...

February 15, 2022, 12:20 pm

Okyo pharma receives us regulatory approval to take dry disease candidate directly into a phase ii trial

OKYO Pharma Ltd said the US regulator has given it the green light to take its dry eye disease treatment directly into a phase II clinical trial. The ...

February 15, 2022, 2:36 am

Okyo pharma receives us regulatory approval to take dry disease candidate directly into a phase ii trial

OKYO Pharma Ltd said the US regulator has given it the green light to take its dry eye disease treatment directly into a phase II clinical trial. The ...

February 15, 2022, 2:36 am

Okyo pharma receives us regulatory approval to take dry disease candidate directly into a phase ii trial

OKYO Pharma Ltd said the US regulator has given it the green light to take its dry eye disease treatment directly into a phase II clinical trial. The ...

February 15, 2022, 2:36 am

Why proqr therapeutics stock got slammed again monday

Analysts are notably more bearish on the company following unhappy news about its leading drug candidat...

February 14, 2022, 6:23 pm


Search within

Pages Search Results: